Season 25 Episode 112
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.
CME information and select publications here.
Published on 2 weeks ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate